CORC  > 中国医学科学院 北京协和医学院
The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries
Sun, Guo-ping; Sun, Yan; Xu, Rui-hua; Xu, Jian-Ming; Li, Jin; Wang, Jin-Wan; Qin, Shukui; Feng, Ji Feng; Ba, Yi; Shen, Lin
2013
会议名称JOURNAL OF CLINICAL ONCOLOGY
会议日期2013-05-20
收录类别CPCI-S
URL标识查看原文
内容类型会议论文
URI标识http://www.corc.org.cn/handle/1471x/6687679
专题中国医学科学院 北京协和医学院
推荐引用方式
GB/T 7714
Sun, Guo-ping,Sun, Yan,Xu, Rui-hua,et al. The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries[C]. 见:JOURNAL OF CLINICAL ONCOLOGY. 2013-05-20.
个性服务
查看访问统计
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。


©版权所有 ©2017 CSpace - Powered by CSpace